A Secret Weapon For M3541
MI-CP151 was a section 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre research To judge several intravenous doses of sifalimumab, in Grownup clients with dermatomyositis or polymyositis (NCT00533091). Major demo targets were being to evaluate the protection and tolerability of sifalimumab in dermatomyositis or polymyo